Apolizumab Explained

Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers.[1] [2] Development was abandoned in 2005, because of toxic effects and lack of efficacy in humans. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia.[3]

Notes and References

  1. Bayes M, Rabasseda X, Prous JR . Gateways to clinical trials . Methods and Findings in Experimental and Clinical Pharmacology . 25 . 9 . 747–771 . November 2003 . 14685303 .
  2. Rech J, Repp R, Rech D, Stockmeyer B, Dechant M, Niedobitek G, Gramatzki M, Valerius T . 6 . A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study . Leukemia & Lymphoma . 47 . 10 . 2147–2154 . October 2006 . 17071489 . 10.1080/10428190600757944 . 24080973 .
  3. Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC . 6 . A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia . Leukemia & Lymphoma . 50 . 12 . 1958–1963 . December 2009 . 19860603 . 8166408 . 10.3109/10428190903186486 . 22328921 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Apolizumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.